(COVID-19 Updates) India Intravenous Anesthetic Market to Surpass US$ 90.4 Million by 2027, At a GAGR of 2.6% | Coherent Market Insights
SEATTLE, May 04, 2021, (PHARMIWEB) —
Intravenous anaesthetics are a class of fast-acting drugs used to achieve total sedation. Propofol, etomidate, ketamine, and barbiturates are some of the most common intravenous anaesthetics. The rising number of surgeries in India is projected to propel the intravenous anaesthetic market in India to new heights during the forecast period. Furthermore, an increase in the number of heart diseases in India is one of the major factors contributing to an increase in the number of surgeries performed in the country. According to the CADI Research Foundation, about 47 million Indians suffered from coronary heart disease in 2010. (CAD). In addition, about 60,000 coronary bypass surgeries are conducted in India each year. Due to the large number of surgeries conducted in India, the intravenous anaesthetic demand in India is expected to expand.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3558
The increasing use of surgical robotics has resulted in advancements in surgical procedures, which is expected to drive the intravenous anaesthetic market in India to expand during the forecast period. Advances of medical products and technology have resulted in a transition away from traditional surgeries and toward minimally invasive procedures. Important advances in surgical techniques have arisen from the use of robotic equipment in minimally invasive surgeries. Robotic surgeries have become more common in India as a result of their adoption. Furthermore, the India intravenous anaesthetic market is projected to rise over the forecast period due to an increase in surgeries.
In addition, anaesthesiologists prefer to use injectable anaesthetics, as they work faster compared to other anaesthetics. IV (Intravenous) anesthetics are typically small and highly lipophilic molecules and being lipophilic, helps to facilitate their rapid preferential distribution into brain and spinal cord, as both the organ are highly vascularized and lipophilic.
India intravenous anaesthetic market growth is attributed to the increasing number of different surgical procedures that depend on IV anaesthesia. For instance, according to Obesity Surgery Society of India data, the weight loss surgeries performed in India are continuously increasing. In 2014, around 8 bariatric surgeries were performed in India and it reached around 20,242 in 2018. Moreover, in India the number of bariatric surgeons increased from 8 to 250 during 2004 to 2018.
Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3558
Key companies contributing in the India intravenous anesthetic market are Baxter International Inc., Maruishi Pharmaceutical Co., Ltd, AstraZeneca Plc, AbbVie Inc., Mylan N.V., Hikma Pharmaceuticals, Fresenius Kabi, Piramal Healthcare, and B. Braun Melsungen AG.
- India Intravenous Anesthetic Market, By Type:
- India Intravenous Anesthetic Market, By End User:
- Company Profiles
- AstraZeneca Plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Fresenius Kabi
- AbbVie Inc.
- Baxter International Inc.
- Braun Melsungen AG
- Maruishi Pharmaceutical Co.,Ltd
- Piramal Healthcare
- Hikma Pharmaceuticals
- Mylan N.V.
- AstraZeneca Plc*
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/india-intravenous-anesthetic-market-2880
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
- CDN Newswire